1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 3, 2013, Pages 423-433

  Käsnänen, Heikki ^a,b   Minkkilä, Anna ^a,b   Taupila, Susanna ^a   Patel, Jayendra Z ^a   Parkkari, Teija ^a   Lahtela Kakkonen, Maija ^a   Saario, Susanna M ^c   Nevalainen, Tapio ^a   Poso, Antti ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ORION CORPORATION   (Finland)

^c Charles River Discovery Research Services Finland   (Finland)

Author keywords

Drug design; FAAH; MAGL Inhibitors Molecular docking

Indexed keywords

ENZYME; ENZYME INHIBITOR; FATTY ACID AMIDASE; HYDROLASE; LIGAND; MONOACYLGLYCEROL; OXADIAZOLE DERIVATIVE;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; BRAIN; ENZYME INHIBITORS; MALE; MODELS, MOLECULAR; MONOACYLGLYCEROL LIPASES; OXADIAZOLES; RATS; RATS, WISTAR;

EID: 84878526504     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.03.015     Document Type: Article

References (71)

1. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guideposts for drug discovery Drug. Discov. Today. 10 2005 464 469
2. J.P. Alexander, and B.F. Cravatt The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases J. Am. Chem. Soc. 128 2006 9699 9704
3. Y. Ben Ali, H. Chahinian, S. Petry, G. Muller, R. Lebrun, R. Verger, F. Carrière, L. Mandrich, M. Rossi, G. Manco, L. Sarda, and A. Abousalham Use of an inhibitor to identify members of the hormone-sensitive lipase family Biochemistry 45 2006 14183 14191
4. T. Bertrand, F. Augé, J. Houtmann, A. Rak, F. Vallée, V. Mikol, P.F. Berne, N. Michot, D. Cheuret, C. Hoornaert, and M. Mathieu Structural basis for human monoglyceride lipase inhibition J. Mol. Biol. 396 2010 663 673
5. T. Bisogno, G. Ortar, S. Petrosino, E. Morera, E. Palazzo, M. Nalli, S. Maione, V. Di Marzo, and Endocannabinoid Research Group Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo Biochim. Biophys. Acta. 1791 2009 53 60
6. J.L. Blankman, G.M. Simon, and B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem. Biol. 14 2007 1347 1356
7. D.L. Boger, H. Sato, A.E. Lerner, M.P. Hedrick, R.A. Fecik, H. Miyauchi, G.D. Wilkie, B.J. Austin, M.P. Patricelli, and B.F. Cravatt Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide Proc. Natl. Acad. Sci. USA 97 2000 5044 5049
8. A.L. Bowman, and A. Makriyannis Refined homology model of monoacylglycerol lipase: toward a selective inhibitor J. Comput. Aid. Mol. Des. 23 2009 799 806
9. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
10. C.E. Chang, W. Chen, and M.K. Gilson Ligand configurational entropy and protein binding Proc. Natl. Acad. Sci. USA 104 2007 1534 1539
11. J.W. Chang, M.J. Niphakis, K.M. Lum, A.B. Cognetta, C. Wang, M.L. Matthews, S. Niessen, M.W. Buczynski, L.H. Parsons, and B.F. Cravatt Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates Chem. Biol. 19 2012 579 588
12. R. Chen, J. Zhang, Y. Wu, D. Wang, G. Feng, Y.P. Tang, Z. Teng, and C. Chen Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease Cell Rep. 2 2012 1329 1339
13. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
14. W.A. Devane, F.A. Dysarz, M.R. Johnson, L.S. Melvin, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 34 1988 605 613
15. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
16. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug. Discov. 7 2008 438 455
17. V. Di Marzo The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation Pharmacol. Res. 60 2009 77 84
18. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, S. Kathuria, and D. Piomelli Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. USA 99 2002 10819 10824
19. M. Feledziak, D.M. Lambert, J. Marchand-Brynaert, and G.G. Muccioli Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis Recent. Pat. CNS. Drug. Discov. 7 2012 49 70
20. C.J. Fowler Monoacylglycerol lipase - a target for drug development? Brit. J. Pharmacol. 166 2012 1568 1585
21. J. Fu, G. Bottegoni, O. Sasso, R. Bertorelli, W. Rocchia, M. Masetti, A. Guijarro, A. Lodola, A. Armirotti, G. Garau, T. Bandiera, A. Reggiani, M. Mor, A. Cavalli, and D. Piomelli A catalytically silent FAAH-1 variant drives anandamide transport in neurons Nat. Neurosci. 15 2011 64 69
22. Y. Gaoni, and R. Mechoulam Isolation, structure, and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86 1964 1646 1647
23. D.J. Gustin, Z. Ma, X. Min, Y. Li, C. Hedberg, C. Guimaraes, A.C. Porter, M. Lindstrom, D. Lester-Zeiner, G. Xu, T.J. Carlson, S. Xiao, C. Meleza, R. Connors, Z. Wang, and F. Kayser Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors Bioorg. Med. Chem. Lett. 21 2011 2492 2496
24. P.J. Hajduk Fragment-based drug design: how big is too big? J. Med. Chem. 49 2006 6972 6976
25. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug. Discov. Today. 9 2004 430 431
26. J. Huang, and D.F. Bushey Novel 1,3,4-oxadiazol-2(3H)-ones as potential pest control agents J. Agric. Food Chem. 35 1987 368 373
27. M. Kaczocha, S.T. Glaser, and D.G. Deutsch Identification of intracellular carriers for the endocannabinoid anandamide Proc. Natl. Acad. Sci. USA 106 2009 6375 6380
28. C.N. Kapanda, J. Masquelier, G. Labar, G.G. Muccioli, J.H. Poupaert, and D.M. Lambert Synthesis and pharmacological evaluation of 2,4- dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors J. Med. Chem. 55 2012 5774 5783
29. M. Karlsson, J.A. Contreras, U. Hellman, H. Tornqvist, and C. Holm CDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases J. Biol. Chem. 272 1997 27218 27223
30. A.R. King, A. Lodola, C. Carmi, J. Fu, M. Mor, and D. Piomelli A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors Brit. J. Pharmacol. 157 2009 974 983
31. L.E. Kiss, H.S. Ferreira, A. Beliaev, L. Torrao, M.J. Bonifacio, and D.A. Learmonth Design, synthesis, and structure-activity relationships of 1,3,4-oxadiazol-2(3H)-ones as novel FAAH inhibitors Med. Chem. Commun. 2 2011 889 894
32. P. Kolb, and J.J. Irwin Docking screens: right for the right reasons? Curr. Top. Med. Chem. 9 2009 755 770
33. G. Labar, C. Bauvois, G.G. Muccioli, J. Wouters, and D.M. Lambert Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling Chembiochem 8 2007 1293 1297
34. G. Labar, C. Bauvois, F. Borel, J.L. Ferrer, J. Wouters, and D.M. Lambert Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling Chembiochem 11 2010 218 227
35. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug. Discov. 6 2007 881 890
36. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, F.J. Pavón, A.M. Serrano, D.E. Selley, L.H. Parsons, A.H. Lichtman, and B.F. Cravatt Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5 2009 37 44
37. J.Z. Long, D.K. Nomura, R.E. Vann, D.M. Walentiny, L. Booker, X. Jin, J.J. Burston, L.J. Sim-Selley, A.H. Lichtman, J.L. Wiley, and B.F. Cravatt Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proc. Natl. Acad. Sci. USA 106 2009 20270 20275
38. J.Z. Long, X. Jin, A. Adibekian, W. Li, and B.F. Cravatt Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases J. Med. Chem. 53 2010 1830 1842
39. A.M. Malfitano, E. Ciaglia, G. Gangemi, P. Gazzerro, C. Laezza, and M. Bifulco Update on the endocannabinoid system as an anticancer target Expert. Opin. Ther. Target. 15 2011 297 308
40. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, and D.R. Compton Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
41. A. Minkkilä, S.M. Saario, H. Käsnänen, J. Leppänen, A. Poso, and T. Nevalainen Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase J. Med. Chem. 51 2008 7057 7060
42. A. Minkkilä, J.R. Savinainen, H. Käsnänen, H. Xhaard, T. Nevalainen, J.T. Laitinen, A. Poso, J. Leppänen, and S.M. Saario Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors ChemMedChem. 4 2009 1253 1259
43. L. Morera, G. Labar, G. Ortar, and D.M. Lambert Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold Bioorg. Med. Chem. 20 2012 6260 6275
44. A. Moriconi, I. Cerbara, M. Maccarrone, and A. Topai GPR55: current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor Curr. Med. Chem. 17 2010 1411 1429
45. G.G. Muccioli, G. Labar, and D.M. Lambert CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay Chembiochem. 9 2008 2704 2710
46. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
47. V. Naidoo, D.A. Karanian, S.K. Vadivel, J.R. Locklear, J.T. Wood, M. Nasr, P.M. Quizon, E.E. Graves, V. Shukla, A. Makriyannis, and B.A. Bahr Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology Neurotherapeutics 9 2012 801 813
48. M.P. Patricelli, and B.F. Cravatt Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism Biochemistry 38 1999 14125 14130
49. M.P. Patricelli, M.A. Lovato, and B.F. Cravatt Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties Biochemistry 38 1999 9804 9812
50. E. Perola An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 53 2010 2986 2997
51. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Invest. Drug. 11 2010 51 62
52. V. Point, K.V.P. Pavan Kumar, S. Marc, V. Delorme, G. Parsiegla, S. Amara, F. Carrière, G. Buono, F. Fotiadu, S. Canaan, J. Leclaire, and J.F. Cavalier Analysis of the discriminative inhibition of mammalian digestive lipases by 3-phenyl substituted 1,3,4-oxadiazol-2(3H)-ones Eur. J. Med. Chem. 58 2012 452 463
53. S.M. Saario, and J.T. Laitinen Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors Basic Clin. Pharmacol. Toxicol. 101 2007 287 293
54. S.M. Saario, J.R. Savinainen, J.T. Laitinen, T. Järvinen, and R. Niemi Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes Biochem. Pharmacol. 67 2004 1381 1387
55. S.M. Saario, O.M. Salo, T. Nevalainen, A. Poso, J.T. Laitinen, T. Järvinen, and R. Niemi Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes Chem. Biol. 12 2005 649 656
56. S.M. Saario, A. Poso, R.O. Juvonen, T. Järvinen, and O.M. Salo-Ahen Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system J. Med. Chem. 49 2006 4650 4656
57. O.I. Salem, M. Frotscher, C. Scherer, A. Neugebauer, K. Biemel, M. Streiber, R. Maas, and R.W. Hartmann Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids J. Med. Chem. 49 2006 748 759
58. J.R. Savinainen, M. Yoshino, A. Minkkilä, T. Nevalainen, and J.T. Laitinen Characterization of binding properties of monoglyceride lipase inhibitors by a versatile fluorescence-based technique Anal. Biochem. 399 2010 132 134
59. C. Schalk-Hihi, C. Schubert, R. Alexander, S. Bayoumy, J.C. Clemente, I. Deckman, R.L. Desjarlais, K.C. Dzordzorme, C.M. Flores, B. Grasberger, J.K. Kranz, F. Lewandowski, L. Liu, H. Ma, D. Maguire, M.J. Macielag, M.E. McDonnell, T. Mezzasalma Haarlander, R. Miller, C. Milligan, C. Reynolds, and L.C. Kuo Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution Protein Sci. 20 2011 670 683
60. Schoenafinger, K., Petry, S., Müller, G., Baringhaus, K.-H., 2001. Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-one and use thereof for inhibiting hormone-sensitive lipase. WO0166531.
61. Schoenafinger, K., Petry, S., Müller, G., Bauer, A., Heuer H.O., 2003. Preparation of 5-alkoxy-5 3-phenyl-1,3,4-oxadiazol-2(3H)-ones for producing medicaments inhibiting pancreatic lipase. WO2003072098.
62. C.W. Scott, G. Tian, X.H. Yu, K.A. Paschetto, D.E. Wilkins, L. Meury, C.Q. Cao, J. Varnes, and P.D. Edwards Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase Eur. J. Pharmacol. 667 2011 74 79
63. M. Seierstad, and J.G. Breitenbucher Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 51 2008 7327 7343
64. T. Steiner, and G. Koellner Hydrogen bonds with pi-acceptors in proteins: frequencies and role in stabilizing local 3D structures J. Mol. Biol. 305 2001 535 557
65. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku 2-Arachidonoylgylcerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 215 1995 89 97
66. G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, M. Mor, S. Rivara, P.V. Plazzi, C. Park, S. Kathuria, and D. Piomelli Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 46 2003 2352 2360
67. U. Taschler, F.P. Radner, C. Heier, R. Schreiber, M. Schweiger, G. Schoiswohl, K. Preiss-Landl, D. Jaeger, B. Reiter, H.C. Koefeler, J. Wojciechowski, C. Theussl, J.M. Penninger, A. Lass, G. Haemmerle, R. Zechner, and R. Zimmermann Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance J. Biol. Chem. 286 2011 17467 17477
68. K. Tsuboi, Y.X. Sun, Y. Okamoto, N. Araki, T. Tonai, and N. Ueda Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase J. Biol. Chem. 280 2005 11082 11092
69. S. Vandevoorde Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors Curr. Top. Med. Chem. 8 2008 247 267
70. B.Q. Wei, E.S. Lander, M.K. McKinney, B.F. Cravatt, and T.S. Mikkelsen A second fatty acid amide hydrolase with variable distribution among placental mammals J. Biol. Chem. 281 2006 36569 36578
71. J. Wiskerke, C. Irimia, B.F. Cravatt, T.J. De Vries, A.N. Schoffelmeer, T. Pattij, and L.H. Parsons Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study ACS Chem. Neurosci. 3 2012 407 417